| General Information |
| Business: |
(Incorporated in Delaware)
We are a clinical pharmaceutical company focused on developing drugs to treat several types of cancer.
We are conducting clinical trials for several drug candidates in our pipeline:
-
EIK1001 to treat advanced melanoma – Phase 2/3 trials with our 740 patients in 22 countries;
-
EIK1001 to treat Stage 4 non-small cell lung cancer (NSCLC) in about 750 patients in Phase 2 trials – along with trials in the U.S. that involve about 60 patients;
-
EIK1003 and EIK1004 to treat 65 patients with ovarian cancer and 16 patients with breast cancer in Phase 1/2 trials for selective PARP1 inhibitors;
-
EIK1005, a WRN helicase inhibitor, to target tumors in a Phase 1/2 trial set to begin dosing in early 2026.
(Note: Eikon filed its S-1 on Jan. 9, 2026, for its IPO without disclosing the number of shares. Estimated proceeds are $100 million, a placeholder figure.)
|
| Industry: |
BIOLOGICAL PRODUCTS - NO DIAGNOSTIC SUBSTANCES |
| Employees: |
|
| Founded: |
2019 |
| Contact Information |
| Address |
230 Harriet Tubman Way Millbrae, California 94030 |
| Phone Number |
(341) 777-0566 |
| Web Address |
https://www.eikontx.com/ |
| View Prospectus: |
Eikon Therapeutics |
| Financial Information |
| Market Cap |
|
| Revenues |
$0 mil (last 12 months) |
| Net Income |
$-309.52 mil (last 12 months) |
| IPO Profile |
| Symbol |
EIKN |
| Exchange |
NASDAQ |
| Shares (millions): |
0.0 |
| Price range |
$0.00 - $0.00 |
| Est. $ Volume |
$100.0 mil |
| Manager / Joint Managers |
J.P.Morgan/Morgan Stanley/BofA Securities/Cantor |
| CO-Managers |
|
| Expected To Trade: |
|
|
Status:
|
TBA |
| Quiet Period Expiration Date: |
Available only to Subscribers |
| Lock-Up Period Expiration Date: |
Available only to Subscribers |
| SCOOP Rating |
Available only to Subscribers |
| Rating Change |
Available only to Subscribers |
